Table 1.
Characteristics of 173 HIV type 1 infected individuals enrolled in this study of the population pharmacokinetic analysis of nevirapine.
| Parameter | Median [IQR] | >1.5 x ULN (number of patients) | |
|---|---|---|---|
| Age (years) | 41.5 [36.1-48.2] | ||
| Gender M/F (%) | 155/18 (89.6/10.4) | ||
| Weight (kg) | 72 [65-79] | ||
| Race | |||
| Caucasian (%) | 154 (89.0) | ||
| Negroid (%) | 15 (8.7) | ||
| Asian (%) | 4 (2.3) | ||
| Clinical chemistry | |||
| Baseline ASAT (U l−1)** | 14 [11-18] | 14 | |
| Baseline ALAT (U l−1)** | 17 [11-23] | 21 | |
| Baseline GGT (U l−1)** | 18 [11-35] | 36 | |
| Baseline AP (U l−1)** | 72 [60-88] | 3 | |
| Baseline TBR (µmol l−1)** | 13 [10-17] | 9 | |
| Glucose (mmol l−1) | 5.8 [5.3-6.3] | ||
| Creatinine (µmol l−1) | 78 [72-87] | ||
| Albumin (g l−1) | 44 [42-46] | ||
| Total protein (g l−1) | 75 [71-78] | ||
| Amylase (U l−1) | 73 [53-99] | ||
| Creatine kinase (U l−1) | 57 [38-93] | ||
| Clinical immunology at baseline | |||
| CD4/CD8 ratio | 0.3 [0.19-0.49] | ||
| CD4 cell count (106 l−1) | 325 [200-473] | ||
| CD8 cell count (106 l−1) | 1020 [718-1385] | ||
| Molecular biology at baseline | |||
| Plasma log10 HIV-1 RNA (copies ml−1) | <2.30 [<2.30-4.14] | ||
| HCV/no HCV (%) | 10/163 (5.8/94.2) | ||
| HBV/no HBV (%) | 11/162 (6.4/93.6) | ||
ALAT = alanine aminotransferase, AP = alkaline phosphatase, ARV = antiretroviral, ASAT = aspartate aminotransferase, F = female, GGT = gamma-glutamyltransferase, HBV = hepatitis B infection, HCV = hepatitis C infection, IQR = interquartile range, M = male, PI = protease inhibitor, TBR = Total bilirubin, ULN = Upper limit of normal.
**
ASAT n = 167, ALAT n = 167, GGT n = 150, AP n = 166, TBR n = 164.